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The fate of Gd and chelate following
intravenous injection of gadodiamide in rats
Abstract Objective: The biodistri-
bution of gadolinium (Gd) and chelate
was studied in rats injected intrave-
nously with a commercially available
gadodiamide magnetic resonance
contrast agent spiked with trace
amounts of
14C-labelled GdDTPA-
BMA. Methods: Biodistribution of
the
14C-labelled ligand in whole
animals was visualised using quanti-
tative whole-body autoradiography,
and quantified in individual tissue
samples by analysing for radioactivity
using beta-counting. Biodistribution
of Gd was measured by inductively
coupled plasma atomic emission
spectroscopy (ICP-AES) and induc-
tively coupled plasma sector field
mass spectrometry (ICP-SF-MS).
Results: The injected dose was
rapidly excreted, with only 1.0%
remaining in the body at 24 h. The
radioactivity thereafter was mainly
associated with kidney cortex, liver,
lung, muscle and skin, with a similar
rate of clearance for both ligand and
Gd from these tissues. The ratio
between
14C-labelled substance and
Gd was not significantly different
from that of the injected substance in
most tissue samples up to 24 h after
injection; the ratio then slowly
decreased. Conclusions: The data
clearly show that measurements of Gd
concentration alone in tissue samples
from animals injected with Gd-based
contrast agents (GBCAs) cannot be
used as a measure of Gd released
from the ligand. To our knowledge,
such measurements comparing Gd
and ligand concentrations and distri-
bution in tissue samples have not been
published previously for any of the
commercial GBCAs.
Keywords Gadolinium . Contrast
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Introduction
For many years there have been discussions in the
literature relating to the stability of gadolinium (Gd)-
based contrast agents (GBCAs). The recent focus on the
rare, but very serious disorder nephrogenic systemic
fibrosis (NSF), characterised by fibrosis of the skin and
other tissues throughout the body, has led to speculation
about the mechanisms involved in the development of this
disease, and the role that Gd may play if released from the
GBCAs (e.g. see [1–6]). Accordingly, it is of interest to
know how much of the Gd in an injected dose of GBCA
may be released in the body, e.g. by the process termed
dechelation or transmetallation. To our knowledge, there
have been no reliable data in the literature to unequi-
vocally demonstrate whether Gd present in tissues is still
chelated or separated from the chelate. The aim of the
present study was to investigate this area of uncertainty by
analysing tissue samples for concentrations of both chelate
and Gd separately following injection of gadodiamide
(Omniscan, GE Healthcare, Princeton, N.J., USA) contain-
ing
14C-labelled GdDTPA-BMA in rats.
The stability of GBCAs has been studied using different
analytical methods, but much of the published information
is based on in vitro studies performed under conditions that
are far from physiological, and several of the in vivo
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Fax: +47-23-186014studies do not contain sufficient data to support the
conclusions drawn. Missing information in such studies
includes lack of quality control data for any free Gd in the
solutions injected [7, 8], interpreting Gd present in tissue
samples as being due to Gd released from the GBCAs
without measuring the chelate (e.g. [9–12]), or not taking
the amount of extra chelate added to the commercial
preparations into consideration when interpreting data [13,
14]. We therefore initiated a study to investigate the fate of
GdDTPA-BMA following intravenous injection in rats
using analytical techniques that cannot be used in human
studies, such as quantitative whole-body autoradiography
(QWBA) and analyses of tissue samples for the content of
both DTPA-BMA and Gd. Several strategies are, at least in
theory, possible to use in such a study. We have avoided
using
153Gd as, from previous experience, we found that it
may give radiolysis of DTPA-BMA and lead to misinterpre-
tation of results. For instance, any radiolysis of the sample
may complicate the interpretation of the data as dechelation
because the chemical instability of the substance may be
difficult to differentiate from radiolysis. To avoid this, we
radiolabelledthe chelateonlyandinjectedOmniscanwiththe
addition of trace amounts of Gd[
14C]DTPA-BMA intrave-
nously into rats. The content of tissue sample homogenates
from selected organs were quantified for the amount of
14C-
labelled chelate (DTPA-BMA) by using beta-counting, and
for Gd using inductively coupled plasma atomic emission
spectroscopy (ICP-AES) or inductively coupled plasma
sector field mass spectrometry (ICP-SF-MS). Beta-counting
was performed on samples combusted in a sample oxidiser,
i.e. a process where the radioactivity is transferred into
14CO2
and trapped before counting in order to avoid any quenching.
QWBA was used to visualise the biodistribution of the
14C-
labelled chelate in the whole animal.
The data obtained show a very similar rate of clearance
for radioactivity and Gd from most tissues, and that




DTPA-BMA was radiolabelled with
14C in the positions
shown in the insert of Fig. 1; Gd was added, and the Gd
[
14C]DTPA-BMA obtained had a specific activity of
15 mCi/mmol (26.3 µCi/mg). The radiolabelled product
was supplied as a dry substance (GE Healthcare, Cardiff,
UK). Omniscan, i.e. the commercial agent from GE
Healthcare (Princeton, N.J., USA) contains 0.5 M gadodia-
mide (GdDTPA-BMA) and 0.025 M caldiamide (CaDTPA-
BMA). All other chemicals used were of analytical
quality. Water was purified by reverse osmosis, ion
exchanged and filtered through a 0.45-µm filter on a
Milli-Q Reagent Water System (Millipore, Billerica, Mass.,
USA).
Quality control and stability of radiolabelled substance
The radiolabelled substance was tested for radiochemical
purity using HPLC with online radiochemical detection. An
HP 1100 system (Agilent Technologies, Santa Clara, Calif.,
USA) coupled to a Radiomatic 150TR Flow Scintillation
Analyzer (PerkinElmer, Waltham, Mass.) was used with an
ACE 3 AQ, 150×4 mm analytical column (Advanced
Chromatography Technologies, Aberdeen, Scotland) oper-
ated at 25°C. The mobile phase was 0.2 M ammonium
acetate: acetonitrile; 99:1 (v/v) run isocratic at 0.8 ml/min,
and the flow cocktail was Ultima-Flo M (PerkinElmer)
run at 2.4 ml/min. The substance was dissolved in sterile
water to a radioactive concentration of 2.5 MBq/ml, kept
at 6°C, and 10 µl was injected for each analysis. The
radiochemical purity was shown to be greater than 98%;
no changes in the purity profile could be seen after
6 months storage at either 2–8°C or below −15°C. A
typical chromatogram is shown in Fig. 1.






































BMA using a radiochemical
detector. The radiochemical
purity was estimated to be at
least 98% based on such chro-
matograms. The
14C-labelling
positions are shown in the insert
(Gd not shown in order to better
visualise the labelling positions)
1637Animals and experimental design
Male Sprague Dawley rats, weighing 165–205 g, were
obtained from Scanbur, Sweden. The animals were
identified by numbered ear tags and kept in polycarbonate
cages (two per cage). The rats were housed in an animal
room with a light/dark cycle of 12 h, temperature 21±2°C
and relative humidity of 55±10%. They had access ad
libitum to municipally supplied tap water and Rat and
Mouse No. 1 Maintenance Diet (RM1) from Special Diet
Services, UK. All animal experiments complied with local
legal requirements and internal guidelines.
Fifteen rats were randomly allocated to five groups, each
containing three rats. The rats were anaesthetised by isoflu-
rane to surgical level and injected intravenously into a lateral
tail vein with Omniscan containing trace amounts of Gd[
14C]
DTPA-BMA. A dose of 0.5 mmol Gd/kg body weight was
given to each animal. The injection solution contained
0.404 mmol/ml GdDTPA-BMA and 0.0202 mmol/ml
CaDTPA-BMA(excesschelateintheOmniscanformulation)
and 0.00679 mmol/ml Gd[
14C]DTPA-BMA. Thus, approxi-
mately1.7%oftheinjectedGdwasboundtotheradiolabelled
substance and there was approximately three-times more
CaDTPA-BMApresentthantheaddedGd[
14C]DTPA-BMA.
The dose administered in this study was 0.5 mmol/kg,
compared with a standard clinical dose of 0.1 mmol/kg. At 1,
4 ,a n d2 4h ,a n d3a n d7d a y sf o l l o w i n gi n j e c t i o no ft h et e s t
substance, animals were killed with an overdose of 25 mg/ml
Pentothal Natrium (4 ml/kg b.w.). Each rat was immediately
coated with aqueous 2% carboxymethyl cellulose (CMC),
immersed in liquid nitrogen and stored at −20°C until
prepared for QWBA analyses.
QWBA
QWBA analysis was performed as described earlier [15].
In short, the animals were embedded in 2% carboxymethyl
cellulose (CMC), immersed in a hexane/dry ice bath (−80°C)
for 30 min and frozen overnight at −20°C, before sectioning
at a thickness of 25 μm at three to five different levels. The
sections were prepared by using a Leica Cryomicrotome
CM3600 at −20°C and exposed for 7 days to imaging plates
(FUJI BAS III Imaging Plates, Japan) before imaging using a
Fujifilm BioImager Analyzer BAS 2500 with BASReader
Software version 2.21 (Fuji Photo Film). The resulting
images were imported into AIDA software version 3.25
(raytest, Straubenhardt, Germany) for quantification. All
visible organs were measured and compared with the
calibration standards included as detailed previously [15].
QuantificationofradioactivityandGdintissuesamples
From the part of the animal not used for QWBA
(approximately half of each animal), representative sam-
ples of liver, kidney, lung, skin, muscle and bone (femur)
were dissected out. The bone samples were further
separated into bone matrix and bone marrow. The tissue
samples from liver (obtained from each of the three
animals at each time point) were homogenised, and each
homogenate and the tissue samples from the other
organs were divided into two replicates, one for deter-
mination of Gd and one for radioactivity. The bone
marrow samples were not analysed because too little
material was obtained.
The quantification of Gd by ICP-AES and ICP-SF-MS
was carried out as follows: 0.3–1 g of liver, kidney, lung,
skin and muscle (wet weight) were digested with nitric acid
and hydrogen peroxide at 90°C for 4 h in polypropylene
tubes. The samples were analysed by using a Perkin Elmer
Optima 3300 DV ICP-AES instrument (radial mode) and
by using the Gd 336.223-nm emission line for the liver
samples and the Gd 342.247-nm emission line for kidney,
lung, skin and muscle samples. Scandium was used as an
internal standard and analysed by using the 424.683-nm
emission line. Quality control samples were prepared by
spiking the NIST (National Institute of Standards and
Technology, USA) bovine liver SRM 1577b with known
amounts of Gd. The accuracy was within the range 102–
103% of added Gd and the repeatability (within day
precision) was within the range 1.0–1.4% relative standard
deviation (RSD). The detection limit was 0.1 µg Gd/g
tissue. The femur bone matrix samples (0.05–0.2 g) were
digested with nitric acid at 90°C for 3 h in polypropylene
tubes. Europium was added as an internal standard and the
samples were diluted to 50 ml. The bone samples were
analysed by using a Thermo Finnigan Element2 ICP-SF-
MS instrument by using the isotopes
157Gd (analyte) and
153Eu (internal standard) in low-resolution mode. Quality
control samples were prepared by spiking the NIST bovine
liver SRM 1577b and Weifa bone powder (Weifa, Norway)
with known amounts of Gd. The accuracy was within the
range 101–106% and the repeatability was within the range
0.3–2.7% RSD. The detection limit was 0.02 µg Gd/g
tissue.
The radioactivity of the tissue samples was measured
following combustion in a sample oxidizer (Model 307
Packard; PerkinElmer Life and Analytical Sciences,
Boston, Mass.) and beta-counting using a Packard Tri-
Carb 2700 TR liquid scintillation analyzer (PerkinElmer
Life and Analytical Sciences) as described previously [15].
The recovery from the sample oxidiser was found to be
97.5±0.7%.
The following estimates of relative organ weight
(g/100 g body weight) were used to quantify the percentage
of injected dose recovered per organ or tissue as it was not
possible to weigh all organs in this study (when measuring
radioactivity of tissue samples from the part of the animal
not used for QWBA): femur bone matrix 0.4%; kidney,
1.2%; lung, 1.2%; liver, 4.9%; skin and fur, 18%; muscle,
43% (GE Healthcare historical data).
1638Results
Representative QWBA pictures obtained 1, 4 and 24 h, and
3 and 7 days after injection of Omniscan with trace
amounts of
14C-labelled GdDTPA-BMA are shown in
Fig. 2. The image obtained 1 h after injection shows
widespread biodistribution as expected for an extracellular
contrast agent, rapid urinary excretion was illustrated by
high concentrations of radioactivity in the kidney and
bladder. Moreover, radioactivity was observed in the
oesophagus and intestine. As can be seen from the image
taken 4 h after injection, the radioactivity is rapidly
excreted via the urinary tract as previously described [16]
with the highest concentration of the radioactivity present
in the content of the intestine, the kidney cortex, liver and
skin. The images show increased concentrations of the
radiolabelled substance in the intervertebral discs of the
spinal column (observed upto 24 hafter injection, although
visible only in the 1-h image in Fig. 2), in the dermis, and
also as a rim surrounding large bones such as the femur
although not in the plane of section in the pictures shown;
see also data for bone and bone marrow in Table 1). The
images obtained at 3 and 7 days after injection show the
highest concentration of radioactivity in kidney cortex, but
also the presence of radioactivity in some other organs,
including skin/fur. The amounts of radioactivity in the
different tissues/organs estimated from the QWBA images
are detailed in Table 1.
The data obtained after analyses of tissue homogenate
samples from kidney, liver, lung, muscle, skin and femur
bone matrix are given in Tables 2 and 3. These data were
recalculated to be given as percentage of injected dose per
organ; such data are shown for the radioactivity in Fig. 3a
and for Gd in Fig. 3b; in Fig. 3c the sum of these Gd data
and radioactivity data are compared in the same plot. In
tissuescontainingthehighestconcentrationsofradioactivity,
there was an excellent agreement between the quantitative
radioactivity data obtained with QWBA and beta-counting.
For the first four time points the beta-counting data were
105±7% (mean ± standard deviation) of that obtained
from QWBA for kidney and 100±10% for liver. Lower
valuesobtainedwithbeta-countingofskinandfurcompared
withQWBA(69±10%)wereprobablyduetothepresenceof
some muscle tissue in the skin and fur homogenates. Similar
comparisonwas not possiblefor lungand muscle because of
the much lower radioactivity present in these tissues; the
radioactivity was below the quantification limit in the
autoradiography images for muscle by 24 h after injection
(Table 1). As the beta-counting data in general give better
sensitivity and accuracy than the QWBA data, and the beta-
counting data were obtained by analysing the same tissue
samples as those used for Gd analyses, it is only the
quantitative data obtained after sample oxidation and beta-
counting that are described and discussed below. The
quantitative data obtained with the two techniques were
well above the detection limits, i.e. the two analytical
methods gave sufficiently robust data.
As can be seen from Fig. 3, the clearance curves for the
radioactivity and Gd are very similar for all tissues
analysed and do not show significant differences, except
for the femur bone matrix. The data in Fig. 3c show that
0.75±0.08% of the injected dose of Gd was present 3 days
after injection (sum for kidneys, femurs, liver, lung, muscle
and skin) with very similar amounts of DTPA-BMA
present in these samples (0.72±0.04% of the injected
dose). In samples obtained 7 days after injection, 0.54±
Fig. 2 Representative QWBA pictures obtained of rats 1, 4 and 24 h, and 3 and 7 days (from left to right) after injection of Omniscan with
trace amounts of Gd[
14C]DTPA-BMA. See the Materials and methods section for further details
16390.08% of Gd and0.38±0.06%of DTPA-BMAwerepresent
in these samples.
Discussion
The aim of this investigation in rats was to study the fate of
traceamountsof
14C-labelledGdDTPA-BMAinOmniscan,
i.e. the commercial product administered to patients
containing 5% CaDTPA-BMA, after intravenous adminis-
tration. By spiking the Omniscan solution before injection
with Gd[
14C]DTPA-BMA, it was possible to image the
whole body biodistribution of the chelate DTPA-BMA.
Moreover, the radiolabelled chelate and Gd could be
estimated in the same tissue samples taken from the same
animals as those used for QWBA. By spiking Omniscan
(containing excess CaDTPA-BMA) with trace amounts of
Gd[
14C]DTPA-BMA, we could be sure that even if a small
excess of Gd should be present in the laboratory-prepared
Gd[
14C]DTPA-BMA, it would be bound by the excess
Table 1 Mean estimated amounts of
14C-labelled substance in selected organs/tissues (kBq/g tissue) based on the QWBA pictures for rats
injected with Omniscan with trace amounts of
14C-labelled GdDTPA-BMA (DL detection limit)
Tissues Time after injection
1 h 4 h 24 h 3 days 7 days
Adrenal 0.40 0.09 0.08 0.04 0.04
Blood 0.85 0.03 <DL <DL <DL
Blood vessel wall 0.83 0.06 0.04 0.03 <DL
Bone 0.09 0.02 0.02 <DL <DL
Bone marrow 0.26 0.13 0.08 0.04 <DL
Brain 0.05 0.02 <DL <DL <DL
Eye 0.38 0.11 <DL <DL <DL
Fat (brown) 0.32 0.05 0.04 0.02 <DL
Heart 0.31 0.03 0.02 <DL <DL
Intestine (large) 0.60 0.16 0.19 0.11 0.02
Intestine (small) 3.09 0.49 0.10 0.02 <DL
Kidney 4.72 2.25 1.66 1.17 0.51
Liver 0.57 0.17 0.08 0.04 <DL
Lung 0.73 0.06 0.03 0.02 <DL
Muscle 0.18 0.03 <DL <DL <DL
Pancreas 0.45 0.08 0.05 0.03 <DL
Renal cortex 3.36 3.02 2.69 2.19 1.29
Renal medulla 19.26 0.43 0.33 0.28 0.29
Salivary gland 0.40 0.09 0.08 0.04 0.03
Skin and fur 0.56 0.13 0.07 0.04 <DL
Spleen 0.29 0.15 0.11 0.05 0.02
Stomach wall 0.72 0.09 0.04 0.03 <DL
Table 2 Estimated amounts of Gd (µg Gd/g tissue) in selected organs/tissues from rats injected with Omniscan with trace amounts of
14C-labelled GdDTPA-BMA. Data are given as mean ± SD (n=3)
Tissues Time after injection
1 h 4 h 24 h 3 days 7 days
Kidney 72.6±13.2 36.5±7.58 30.0±5.19 23.6±1.04 12.7±0.96
Liver 7.40±2.11 2.44±0.98 1.56±0.21 0.88±0.13 0.53±0.15
Lung 10.4±2.46 1.75±1.01 0.88±0.02 0.71±0.09 0.48±0.02
Muscle 3.20±0.52 0.55±0.11 0.35±0.05 0.21±0.01 0.16
a
Skin 5.36±1.28 1.22±0.28 0.76±0.11 0.52±0.12 0.39±0.16
Bone 6.05±1.62 3.47±0.43 3.55±0.19 4.45±0.49 4.92±0.11
aOnly one sample above limit of quantitation
1640chelate, upon injection to the animal, and therefore would
not have any effect on the data obtained.
The whole-body autoradiography images show higher
concentrations of radioactivity in the intervertebral discs of
the spinal column, in the dermis of the skin, and as a rim
surrounding large bones such as the femur compared with
the surrounding tissues. It could not be determined whether
the rim surrounding large bones is due to binding to the
periosteum (connective tissue around the bone) or the bone
surface. The data thus show that the agent enters different
organs or organ compartments and the clearance kinetics is
different from each.
Regarding discussions about NSF and the presence of Gd
in skin, it should be noted that very similar concentrations of
14C and Gd were present in the samples obtained during the
first 3 days after injection. Thus, the measurements of Gd
only in such samples cannot be used to quantify the amount
of dechelation (release of Gd from the chelate), contrary to
what often is described in the literature (see discussion
below). Of the residual amount of the injected substance
that was left in the rat 3 and 7 days (0.75% and 0.54%,
respectively) after injection of Omniscan spiked with trace
amounts of
14C-labelled GdDTPA-BMA, very small
amounts of Gd (less than 0.2% of the injected dose) were
not co-localised with the intact radiolabelled DTPA-BMA.
Increased amounts of radioactivity in the oesophagus and
intestine could be due to rats ingesting radiolabelled urine
whilst grooming, as well as ingestion of radioactive stools
by coprophagy (Fig. 2, image 1 h post-injection). It was not
possible to obtain reliable estimates of the amount of the
injected dose that may have entered the animals via the oral
route.
To our knowledge, measurements of both Gd and the
chelate in tissue samples from the same animals have not
been published for any of the other GBCAs on the market.
The present data clearly show the importance of measuring
both Gd and the chelate in tissues before drawing any
conclusions about the stability of different agents in animal
studies. It should be stressed that the present data were
obtained using a single dose, which was close to that used
clinically, contrary to much of the animal data reported in
the literature for recovery of Gd in tissue samples, and
which are often obtained following repeated injections of
very high doses of Gd-chelates (up to 20 injections with
25-times the standard clinical imaging dose [11, 12]).
The present data are important in relation to conclusions
drawn in several earlier publications aimed at describing
the stability of GBCAs. Firstly, we would like to stress that
ICP-MS, or similar techniques such as ICP-AES, only
measure the concentration of inorganic metals such as Gd,
and cannot be used to assess whether or not Gd is still
bound to the chelate without using additional methods.
Despite this, there are several publications where this
issue is not addressed, and where the presence of Gd in
tissue samples obtained after intravenous injection is
interpreted as evidence of dechelation of the agents. To
rectify this deficiency in the published literature, our
strategy was to combine ICP-AES/ICP-SF-MS measure-
ments of Gd, together with beta-counting of the radio-
labelled chelate following injection of Omniscan-added
trace amounts of Gd[
14C]DTPA-BMA. Another possible
approach is to use ICP-MS as a detector after chro-
matographic separation, but no such methods are
available, probably because the tissue extraction method
may interfere with the stability of the complex, thus
leading to erroneous results.
As mentioned in the introduction, it is in principle
possible to label the substance with
153Gd and to use
gamma-counting for estimation of the Gd concentration in
tissue samples. However, our experience (unpublished
data) is that labelling with
153Gd causes radiolysis, which
may destroy the chelate and cause release of Gd, leading to
a gross overestimate of dechelation. Another challenge
related to the use of
153Gd-labelled substance (if no excess
chelate is added) is the quality control analyses needed to
show that there is no free
153Gd in the substance injected. It
should be noted that any attempt to analyse for free Gd by
chromatographic methods also includes the risk that the
free Gd will bind to the column material, thus under-
estimating the amount of free Gd present in the solution. It
is well known that following intravenous injection of Gd
salts such as GdCl3 in animals, aggregates of Gd are
formed and are taken up by the reticuloendothelial system,
including the liver, spleen and bone marrow [17]. There-
fore, even minor amounts of free Gd in formulations of
GBCAs injected into animals may lead to significantly
1641
Table 3 Estimated amounts of
14C-labelled substance (dpm/g tissue) in selected organs/tissues from rats injected with Omniscan with trace
amounts of
14C-labelled GdDTPA-BMA. Data are given as mean ± SD (n=3)
Tissues Time after injection
1 h 4 h 24 h 3 days 7 days
Kidney 282,946±40,603 134,611±29,011 103,737±12,053 80,438±3,540 35,256±5,781
Liver 31,296±7,000 9,548±3,075 4,928±739 2,421±207 680±148
Lung 37,712±9,734 6,522±4,262 2,540±228 1,441±177 606±32
Muscle 14,896±3,746 2,979±1,505 1,515±334 942±32 490±50
Skin 20,023±4,090 5,014±899 2,828±268 1,736±25 933±172
Bone 18,179±8,852 5,893±1,220 3,275±102 1,833±183 908±150increased uptake of Gd in these tissues, seriously interfer-
ing with the estimate of Gd uptake in tissue due to release
from the chelate.
There are examples in the literature where the appro-
priate data to show the absence of free
153Gd in the
injection solution are not given, but despite this, the
153Gd
content of tissue samples is taken as evidence of released
Gd [7, 8]. In addition, there are also studies with non-
radiolabelled Gd where the presence of the metal in
tissue samples is also interpreted as being due to Gd
released from its chelate [9–12], although without also
measuring the chelate. As shown from the present study,
this cannot be taken as evidence of dechelation.
Moreover, several authors have interpreted the Zn
content in human urine following injection of various
GBCAs to be due to differences in their stability [13,
14], without appreciating that the urine Zn content can
be fully accounted for by Zn binding to the extra chelate
present in the GBCA formulations (e.g. CaDTPA-BMA
in Omniscan). Okazaki et al. [18] reported that 92% of
CaDTPA-BMA injected into rats was excreted in urine
in the same form as it was injected; approximately 7%
was excreted as the ZnDTPA-BMA and approximately
1% as CuDTPA-BMA. By assuming a similar binding of
Zn to CaDTPA-BMA in humans to that in rats, one
should expect 7% of the injected dose of CaDTPA-BMA
present in Omniscan to be excreted as ZnDTPA-
BMA, corresponding to 0.35% of the injected dose of
GdDTPA-BMA.
Several authors have reported increased concentrations
of Gd in skin obtained from NSF patients, and have
interpreted this as most likely to be due to accumulation
within intracellular organelles, e.g. lysosomes, or to
extracellular localisation of insoluble Gd phosphates [19–
21]. These authors did not consider the possibility of
GBCAs taken up via endocytosis, e.g. in cells such as
macrophages or fibroblasts. Further studies are needed to
understand the exact localisation and form of Gd observed
at these sites, as well as their relevance, if any, to the
development of NSF.
In the present study we have investigated the fate of both
Gd and chelate after intravenous injection of Omniscan
spiked with Gd[
14C]DTPA-BMA in normal male Sprague
Dawley rats. It is not known to what extent the fate of the
GBCA in rats resembles that in humans, or to what extent
the slower excretion of GBCAs in patients with renal
impairment will impact on the behaviour of GBCA
following intravenous injection. Clearly, more work is
needed to understand how GBCAs are linked to the
aetiology of NSF.
Conclusion
To the best of our knowledge, the present investigation
has for the first time measured the in vivo tissue
concentration of both Gd and chelate (DTPA-BMA) after
administration of Omniscan containing trace amounts of
Gd[
14C]DTPA-BMA. The clearance of both Gd and
DTPA-BMA from tissue samples was practically iden-
tical. Most of the administered dose was excreted
rapidly, with approximately 1% of the material still to



































































































Time after injection (days) 
Fig. 3a–c Analyses of tissue homogenate samples obtained from
kidney (●), liver (■), lung (▲), muscle (○), skin (□), and femur bone
matrix (− with dotted line) at 4 and 24 h, and 3 and 7 days after
injection of Omniscan with trace amounts of Gd[
14C]DTPA-BMA. a
The percentage of injected dose of the radioactivity per organ is
shown for all tissues at all time points. b The percentage of the
injected dose of Gd is shown for all samples at all time points. c The
sum of the radioactivity (◊) and Gd (♦) data for the six tissues shown
in a and b is compared in the same plot. The 1-h data are not
included in the figure in order to expand the y-scale for the later time
points14C-labelled substance and Gd was very similar in
almost all tissue samples up to 3 days after injection.
These data clearly show that measurements of Gd
concentration in tissue samples cannot be used as a
measure of Gd released from the chelate. Previous
publications that have restricted tissue measurement to
Gd only as an indication of in vivo dechelation should
be reviewed in the light of the findings we have reported
in this investigation.
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